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Introduction
This document has been prepared by the EU Civil Society Forum on Drugs (CSF) in 
order to feed the perspectives of civil society organisations into the development of 
the new EU Drug Strategy and Action Plan, as well as into national drug policies. The 
CSF represents a diverse group of European organisations that provide health and 
social services, advocate for more effective drug policies and represent affected 
communities. This document was produced on the basis of a one-year consultative 
process, the idea being that civil society can add value and should have a strong 
voice in helping to formulate drug policy at all levels—local, national and EU-
wide. This paper therefore aims to present the consensus position of the CSF with 
regard to the new EU Strategy on Drugs.
The CSF calls on the European Commission and the Danish and forthcoming Cypriot 
EU Presidencies, along with the Member States, to draw on the recommendations 
contained in this report when preparing the next EU Drugs Strategy and Action Plan.
What is the Civil Society Forum on Drugs (CSF)?
The EU Civil Society Forum on Drugs (CSF) serves as a platform for an informal 
exchange of views and information between the European Commission and civil 
society organisations with the following objectives:
• feed grass-roots experience into Commission proposals:
• contribute to the work on monitoring the EU Drugs Action Plan (2009-12);
• support the Commission’s work to prepare the new EU drugs policy 
framework.
The Forum was originally established in response to the ‘Green Paper on the Role of 
Civil Society in Drugs Policy in the European Union’, in which the European 
Commission expressed a desire to ‘place the specific experience and knowledge of 
civil society at the disposal of the policy making process at EU level in a practical and 
sustainable form’.1
All European Union decision-making bodies (including the Council of the European 
Union, the European Commission, the European Parliament and the EU agencies) 
have committed to a process of public consultation, including civil society, through 
the Lisbon Treaty and the White Paper on European Governance.
1 http://eur-lex.europa.eu/LexUriServ/site/en/com/2006/com2006_0316en01.pdf .
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In 2011, 35 organisations became CSF members for a two-year period.2 They have a 
variety of perspectives and experiences which influence how they perceive and 
interact with drug policy issues. Hence, on each subject the Forum conducts a 
thorough consultation process in order to reach a consensus position. The CSF is 
organised and administrated by the European Commission.
Why Involve Civil Society?
The meaningful involvement of civil society and particularly affected groups has 
become the central principle for the shaping of policies in the field of health and 
social care. Members of civil society have specialised knowledge that enriches the 
policy debate. They have access to information, experiences and perspectives that 
are different from those that governments bring to the discussion.
1. The involvement of civil society increases the legitimacy of European processes. 
Civil society members represent unique EU-wide and Member State 
constituencies, and their inclusion enhances democratic and transparent 
decision-making. Civil society can also help to disseminate information, thereby 
leading to a broader public understanding of policy issues.
2. Engaging civil society in policy making ensures that different aspects of the drugs 
problem are raised by the groups concerned. 3
3. Civil society is best placed to advocate for and serve the interests of vulnerable 
and socially excluded groups, including those most affected by drug policies. 
Moreover, in formulating and implementing EU and Member State drug policy, 
certain functions can only be fulfilled effectively through involvement with civil 
society organisations.
4. Civil society organisations can play a significant role in the independent 
monitoring and evaluation of policies and programmes, conceptualising and 
initiating innovative solutions to social problems, mobilising communities, 
implementing programmes, delivering services, representing and advocating for 
the interests of affective communities and consulting with affected groups.
5. Civil society involvement can improve the allocation of financial and human 
resources in priority areas to ensure equal and effective distribution.
Recommendations for EU and National Drug Policies
We recommend that the following general principles and specific recommendations 
be reflected in the new EU Strategy on drugs, as well as in national drug strategies 
and their action plans:
General Principles for Drug Policies
1. Drug policies and practices must be balanced, integrated, evidence-based and 
focused on public health.
2. Human rights must be fully respected in drug policies and practices and all drug 
control activities that are undertaken or promoted should be in line with human 
rights obligations, including those that fall under the relevant EU and UN 
Charters, in particular the EU Charter of Fundamental Rights.  
3. Drug policies should refocus their attention on the needs of vulnerable groups. 
These include people who use drugs, young people and children, as well as 
2 Further details on the Civil Society Drugs Forum (including a full list of membership) can be found at 
the European Commission's Drug Control Policy Website: http://ec.europa.eu/justice/anti-drugs/civil-
society/index_en.htm .
3 Adapted from S. Ripinsky and P. Van Den Bossche (2007) NGO Involvement in International 
Organisations: A Legal Analysis London: British Institute of International and Comparative Law: 11–
12.
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women, migrants and mobile populations, prisoners, sex workers, LGBT people 
(Lesbian, Gay, Bisexual and Transgender) exposed to environments where drug 
use occurs and members of vulnerable social-economic communities who may 
be disproportionately affected by drugs and drug policies.
4. Drug policies should renew their focus on approaches involving evidence-based 
demand reduction, including prevention, early intervention, treatment, harm 
reduction, rehabilitation and social reintegration.
5. There should be greater consistency between drug policies and practices. This 
means that drug policies should be fully implemented in practice, and practice 
should be routinely monitored and evaluated, with lessons learnt incorporated 
into policy as needed.
6. Drug policies should incorporate learning and sharing of knowledge and 
experience across local, national, EU and international levels in order to improve 
drug policies in line with evolving practices and understanding.
7. There should be greater emphasis on providing drug-related services within the 
criminal justice system, with services and interventions continuing during the 
post-release period.
8. Drug policies should be developed and implemented at EU level through better 
coordination among all relevant stakeholders, including Member States, relevant 
Directorates-General, the European Parliament and civil society.
9. Evaluation should be considered as an essential element of effective drug policy.
Civil Society Engagement
1. Civil society should be meaningfully involved in national and EU drug policy 
planning, implementation, monitoring and evaluation.
Rationale: Public consultation is a basic principle of democratic societies and 
participatory democracy.4 All European Union decisions are submitted to this process 
through the adoption of the Lisbon Treaty and the White Paper on European 
Governance,5 which outlined the principle of involving citizens, including organised 
groups of citizens, in public dialogue.6
The European Commission Green Paper on the role of civil society in drugs policy7 
stated: ‘The aims of involving civil society are to support policy formulation and 
implementation through practical advice, to ensure an effective two-way information 
flow and to stimulate networking among the various organisations.’. Similarly, the UN 
also emphasises the importance of involving civil society, outlining the need to 
strengthen the role of civil society, invest in partnerships and focus on country 
levels.8
If government organisations and EU structures can work effectively with civil society, 
drug policies are more likely to be grounded in the ‘real world’ experience and 
therefore have a greater chance of being implemented effectively.
Implementation
4 Treaty of Lisbon http://europa.eu/lisbon_treaty/full_text/index_en.htm .
5 European Commission, 2007 WHITE PAPER Together for Health: A Strategic Approach for the EU 
2008-2013 http://ec.europa.eu/health/ph_overview/Documents/strategy_wp_en.pdf .
6 Treaty of Lisbon http://europa.eu/lisbon_treaty/full_text/index_en.htm .
7 European Commission, 2007 Green paper on the role of civil society in drug policy.
8 We the peoples: civil society, the United Nations and global governance. Report of the Panel of 
Eminent Persons on United Nations–Civil Society Relations. United Nations General Assembly. 
A/58/817. 11 June 2004.
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 The European Commission should continue supporting, facilitating and ensuring 
the accountability of civil society involvement including the EU Civil Society 
Forum on Drugs (CSF). It should facilitate the building of a direct linkage between 
the CSF and the Horizontal Group on Drugs.
 The Member States should directly involve civil society representatives in 
national drug policy bodies and, where relevant, support the creation and ongoing 
work of national civil society forums on drugs.
 All EU bodies should promote and support the meaningful involvement of civil 
society in drug policy outside the EU and in international drug policy.
2. Funding and other support should be provided for civil society initiatives in 
a range of drug policy issues, including involvement in policy, its 
implementation, networking and capacity building.
Rationale: Civil society engagement and involvement enhance policy and inform 
practice. However, much of civil society is poorly funded, which means that 
organising civil society at national and European levels is challenging. Hence, the 
engagement of civil society needs the support of statutory authorities.
This support could take the form of enabling networks of civil society groups to come 
together or enabling civil society members to organise themselves. Funding through 
the Drug Prevention and Information Programme has made this possible to a certain 
extent, with the objective of ‘involving civil society in the implementation and 
development of the European Union Strategy on Drugs’.
The challenge, however, is how to resource civil society groupings which currently 
have little or no funding and lack the infrastructure to bid for this and similar funding 
streams.
Implementation
The European Commission should strengthen the EU Drug Prevention Programme 
and ensure that civil society has access to other financial mechanisms, specifically 
by:
 financing civil society organisations to strengthen national networks and 
advocacy mechanisms in the EU and the neighbouring countries;
 ensuring that bottom-up local and national experiences are included via EU, 
regional and international networks;
 stimulating and funding research on the effectiveness of empowerment and 
civil society strategies;
 supporting the engagement of civil society in drug policy outside the EU and 
at global level.
A Comprehensive and Balanced Approach
3. Drug policy working structures at EU and Member State levels should reflect 
the multi-disciplinary nature of the drugs issue. Sectors such as justice, social 
affairs, health, education, law enforcement, drug-related service providers, 
academia, local communities, and other sectors should be engaged, including 
civil society and people affected by drugs.
Rationale: The World Health Organisation defines health as ‘a state of complete 
physical, mental, and social wellbeing and not merely the absence of disease or 
infirmity’. In applying this definition to a multifactorial, health-based approach to drug 
policy, the complex and myriad issues surrounding drugs must be recognised and 
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addressed, safeguarding the health and wellbeing of all those affected by the 
problem.
Furthermore, there is often a gap between the knowledge and experience of local 
and community-based practitioners and national and regional level policy-making 
processes. More ‘bottom up’ communication between law enforcement, health, 
treatment and social reintegration facilities could help ensure the physical and mental 
health and rights of people affected by drug policy, thus maximising limited human 
and economic resources. Moreover, effective drug policies should be derived from a 
combination of real-life experience and approaches based on scientific evidence, 
alongside a clear definition of goals and an emphasis on accountability.
Multidisciplinary approaches, therefore, help address the barriers which prevent the 
full implementation of existing policy and the translation of good practice into policy 
reform. Guidelines from social, health, education and justice bodies and NGOs 
should be concordant so as to reinforce the principle of partnerships. Moreover, a 
range of approaches, based on evidence of effectiveness, should be integrated with 
a view to identifying and resolving drug-related problems experienced by individuals, 
families and communities.
Implementation
 All Member States and the EU Council, with the support of the European 
Commission, should establish national and EU drug policy working structures that 
engage policymakers with representatives from the fields of justice, social affairs, 
health, education, law enforcement and other sectors, including groups of people 
affected by drugs and civil society.
 To support those working structures, Member States and the European 
Commission should promote cooperation among policymakers, practitioners and 
other stakeholders in sharing knowledge and expertise-based needs and 
challenges, thereby ensuring a practical and sustainable drug policy design and 
implementation strategy. The European Commission should support methods 
such as open coordination to help Member States develop drug policies in the 
areas of drug demand reduction, in order to learn from each other’s evolving 
policies and practices.
4. Poverty, deprivation, social inequality, discrimination and stigma must be 
given their full and proper place in all considerations of drug demand 
reduction policies, at local, Member State and European levels.
Rationale
There is a substantial body of evidence which highlights links between problem drug 
use poverty and deprivation and social inequality.9
As far as adults are concerned, while ‘recreational’ drug use is not necessarily more 
prevalent among socially excluded groups, more harmful patterns of drug use are 
typically reported by people who are unemployed, unqualified, in financial difficulties 
and homeless or living in rented or unstable accommodation.1011 Socio-economic 
deprivation is associated with drug dependence, but not drug use.12
9 Scottish Drug Forum. Poverty and drug use — a literature review, 2007.
10 Coulthard M, Farrell M, Singleton N, Meltzer H. Tobacco, alcohol and drug use and mental health. 
Report based on the analysis of the ONS Survey of Psychiatric Morbidity among Adults in Great 
Britain carried out in 2000 for the Department of Health, the Scottish Executive Health Department and 
the National Assembly. London: TSO, 2002.
11 Wadsworth EJK, Moss SC, Simpson SA, Smith AP. Factors associated with recreational drug use. 
Journal of Psychopharmacology, 2004;18:2:238-248.
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It is also clear that countries with a lower level of social inequality and greater social 
cohesion have smaller populations of problem drug users per head of population. 
Thus, addressing poverty and social inequality over the long term will have a 
significant impact on levels of problem drug use.
Social inequality and poverty will also be issues in many people’s rehabilitation and 
social reintegration, including long-term recovery. Recovery and social reintegration 
may be understood differently across and within Member States.13 However, the 
recovery process often involves maximising health and wellbeing and participation in 
the rights, roles and responsibilities of society. 14 In addition to medical services, 
social reintegration should also entail addressing the wider social needs of people 
affected by drugs (employment, housing and civil participation). This might lead to 
greater control over the drug problem, including relapse prevention. Linked to this, 
evidence is also emerging of current recession's impact on the scale of drug 
problems and related harms, along with inequalities in society.
Implementation
 The  EU Council  and  the  Member  States  should  take  specific  measures  and 
provide funding to address the social/health/economic inequalities,  stigma and 
discrimination surrounding problem drug use in the new EU drug strategy and 
national  strategies.  Special  attention would  be required in  communities where 
poverty and social deprivation are more prevalent and where people affected by 
drugs have special needs, such as children, young people, women and others in 
vulnerable situations.
 The EU Council  and the Member States should address drug prevention and 
problem drug use issues in EU and national programmes on  social, economic, 
education and health policies to reduce inequalities within and across Member 
States.  
5. The EU and national drugs strategies should renew their focus on drug 
demand reduction and integrate a balanced demand reduction approach, 
including prevention, early intervention, treatment, harm reduction, 
rehabilitation and social reintegration.
Rationale: Drug policies and strategies that have only focused on supply reduction 
have not been able to curb the global illicit drug market. Indeed, as demand has 
remained high, successful supply reduction approaches to the production and 
trafficking of a drug in a particular region has led to an increase in production and/or 
trafficking of this drug in another region of the world (the "balloon" effect).15 Drug 
policies should therefore seek to tackle the illicit drug market by adopting a balanced 
approach targeting demand and supply, as well as focusing on how demand and 
supply interact with each other. The EMCDDA (European Monitoring Centre for 
Drugs and Drug Addiction), in collaboration with national focal points, publishes 
country reports and other analyses detailing patterns of drug use and national 
responses. National and EU drug demand reduction policy should be better tailored 
and responsive to identified trends and challenges.
12 Von Sydow, K., Lieb, R., Pfister, H. et al. (2002), ‘What predicts incident use of cannabis and 
progression to abuse and dependence? A 4-year prospective examination of risk factors in a community 
sample of adolescents and young adults’, Drug and alcohol dependence 68(1), pp. 49–64.
13 Journal of Substance Abuse Treatment (2007). Special Section: Defining and Measuring Recovery. 
2007 (33) 221-228.
14 UK Drug Policy Commission (2008). Recovery Consensus Group. A vision of recovery. .
15 Trimbos Institute and RAND. A Report on Global Illicit Drugs Markets 1998-2007. Full Report. 
Commissioned by the Commission of the European Communities (contract JLS/2007/C4/005). 
Available at: http://ec.europa.eu/justice/anti-drugs/files/report-drug-markets-full_en.pdf .
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In terms of demand reduction, drug strategies and approaches need to address the 
underlying social and economic determinants of health, including drug dependence. 
The harmful effects of drug use can be compounded where communities have 
problems, such as poverty, socio-economic deprivation and homelessness, or where 
sections of the population such as women or minority communities experience 
disadvantage. Reducing social and economic inequalities and building social 
cohesion have the potential to reduce the demand for drugs, and the related harms 
done to individuals, communities and society at large. For those who use drugs, 
services should be available to address a range of needs, from harm reduction to 
drug dependence treatment, rehabilitation and social reintegration.
Implementation
 The  Member  States,  with  the  support  of  the  European  Commission,  should 
ensure that the national and EU drugs action plans and budgets strike a balance 
within  their  drug  demand  reduction  strategy  in  terms  of  prevention,  early 
intervention, treatment, harm reduction, rehabilitation and social reintegration.
 In  designing  and  implementing  national  drug  policies,  Member  States  should 
strike  a  balance  between  reducing  drug  supply  and  demand,  allocating 
appropriate  resources  to  ensure  that  demand  reduction  is  given  appropriate 
weight in national drug policies.
 The European Commission should track investment and gaps in drug demand 
reduction and share this information to help improve existing drug policy.
 The European Parliament,  the Council  and the European Commission should 
continue supporting drug demand reduction through the EU Drug Prevention and 
Information  Programme  as  a  separate  programme  or  under  the  Rights  and 
Citizenship  Programme (2014-2020),  The  Health  for  Growth  Programme and 
other programmes.16
Criminal Justice
6.  Diversion  from prosecution  should  be  provided  for  possession  of  small 
amounts of drugs for personal use.17 
Rationale: While criminal justice systems vary considerably across Europe, a likely 
early  outcome for  a personal-use drug-law offender  is  dismissal.  However,  some 
Member States are more likely than others to issue suspended or prison sentences.18 
Criminal  records  for  drug  users  can  lead  to  reduced  social  and  employment 
prospects  and  increased  social  exclusion.  Engagement  with  the  criminal  justice 
system is not only costly for individuals but also for wider society with significant legal 
and police resources devoted to processing such cases.
Implementation
 The Member States should consult national stakeholders, including civil society, 
on how best to introduce policies promoting diversion from prosecution for small 
amounts  of  drugs  for  personal  use.  On the  basis  of  this  consultation,  action 
should be taken to change the legislation and other policy where needed, and to 
ensure that the new policy is supported within the national drug policy framework.
16 Further details on the recommendation are available in the CSF letter of January 2012 concerning the 
European Commission's proposals in regard to the upcoming ‘Health for Growth’ programme (DG 
SANCO), and the re-organisation of DG JUST's programmes and other funding opportunities for drug 
demand reduction.
1716 members of the CSF (Civil Society Forum on Drugs) recommend that the decriminalisation of 
possession of small amounts should be considered. Their position is explained in Annex IV
18 EMCDDA. Drug offences: sentencing and other outcomes. Selected Issue. Lisbon, November 2009. .
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 The European Commission should promote good practices and share lessons 
learnt by Member States, civil society and other stakeholders, on progress 
towards diversion from the criminal justice system.
7. A range of alternatives to custody should be put in place for people with 
drug dependency.
Rationale: According to the EMCDDA Annual Report 2011, in the European Union 
the proportion of sentenced prisoners convicted for drug law offences (including 
possession, production, trafficking and dealing) ranges from 3% to 53 %. This is 
costly for Member States and it is questionable whether it is effective in rehabilitating 
people with drug problems. For example, according to the 2005 EMCDDA report on 
the issue, the average cost of keeping someone in the UK prison system is EUR 145 
per day, compared to less than EUR 60 for community-based drug treatment.19 There 
is also evidence that alternatives to imprisonment lead to greater improvements in 
health and social wellbeing, and also reduce drug-related crime.
Implementation
 The Member States should develop alternatives to custody and, where 
necessary, amend their penal codes, allocate relevant funding and introduce 
policies to ensure that such systems function as intended.
 The European Commission should fund and assist in the development of 
alternatives to custody and share good practice across Europe.
 The European Commission should prepare and share with the Member States, 
including policy makers responsible for drug policy and those responsible for 
justice systems, evidence outlining the benefits, challenges and good practices in 
the implementation of alternatives to custody.
8. Services for problem drug users in custody, detention and prison should be 
evidence-based  and  mirror,  as  well  as  work  with,  those  available  in  the 
community.
Rationale: While there is a lack of comparable data on prison inmates with drug 
problems, we know that drug use is consistently higher among this population than it 
is in the general population.20 WHO/Europe reports that illicit drug use varies widely 
from 22% to 86 % in prisons in the European Union.21 According to the EMCDDA, the 
harmful practices of drug use (such as needle sharing) are more prevalent within the 
prison population.
It is therefore necessary to provide drug demand reduction services for problem drug 
users in prison in order to respond to the risks that this population faces while within 
the prison setting. The evaluation of the EU Council’s Recommendation 2003/488/EC 
of  18  June  2003  on  the Prevention  and  Reduction  of  Health-Related  Harm 
Associated  with  Drug  Dependence found  major  gaps  in  drug-related  services  in 
closed  settings  compared  with  those  in  the  community  across  the  EU  Member 
States.
19 Similarly, in Italy the daily costs of rehabilitation in the community are 37 EUR per person, as 
indicated in San Patrignano. Annual Mission Report. 2009, available at: 
http://www.sanpatrignano.org/pdf/Bilancio_09_en.pdf .
20 EMCDDA (2011) Annual Report 2011: The State of the Drugs Problem in Europe. Luxembourg: 
Publications Office of the European Union, 2011.
21 WHO/Europe. Prisons and health: Facts and Figures. Accessed on 9 March 2012 at:
http://www.euro.who.int/en/what-we-do/health-topics/health-determinants/prisons-and-
health/facts-and-figures.
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While most problem drug users are better dealt with outside the prison environment, 
there can be opportunities for those in prison to address their problems. Thus, the 
help they receive should be equivalent to that provided in the community.
Implementation
 The Member States should establish action plans to address current legislative, 
social and other challenges and identify concrete mechanisms for ensuring that 
problem drug users have access to high-quality services which are equivalent to 
those available in the community.
 The  European  Commission  should  facilitate  and  support  the  adoption  and 
dissemination of quality standards for drug demand services in closed settings in 
the EU.
9. Continuity of drug demand reduction services must be provided for people 
dependent on drugs on entering detention and prison from the community, and 
on their release.
Rationale: When problem drug users are imprisoned, community treatment and care 
are often discontinued. This leads to increased health and social harms (blood-borne 
viruses,  overdoses,  self-harming,  suicide and breakdown of  family  contacts).  The 
same lack of continuity of care can be seen when people leave prison and return to 
the community. Poor continuity of care and insufficient preparation for release result 
in greater harms to individuals (for example an increased risk of overdose on release 
from prison) as well as less efficient and less cost-effective services. Programmes for 
building life skills which are focused on preparation for release have proven to reduce 
those harms and improve the social reintegration of individuals.
Implementation
 The Member States should oversee and implement mechanisms that ensure that 
well-coordinated health, social and other services are in place. They should also , 
provide continuity of care and support to problem drug users on admission to 
custody, during detention and imprisonment, and upon release.
 The European Commission should assess and promote good practice models of 
continuum of care for people entering closed settings from the community and 
vice versa across the Member States.
Human Rights  
10. Drug policies should reinforce Europeans’ rights as outlined in the EU 
Charter on Fundamental Rights, particularly the right to health care.
Rationale: As a general rule, EU and national drug policies outline respect for 
equality, citizens' rights and justice as fundamental principles, without specifying how 
these principles should be translated into practice. The EU Charter of Fundamental 
Rights explicitly outlines a series of rights that are particularly relevant to drug policy: 
the right to non-discrimination; the right to health; the rights of the child to protection; 
the right to justice and legal support; as well as the rights to education and to fair and 
just working conditions; the right to social security and social assistance; the right to 
a fair trial and standards of due process; the right to avoid torture, cruel, inhumane or 
degrading treatment, punishment or arbitrary detention; as well as cultural or 
indigenous rights, among others.
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On the other hand, problem drug users belong to a marginalised group of society and 
often face stigma and discrimination, as do their children and families. Inadequate 
enjoyment of their rights deepens not only their economic and social and other 
exclusion but increases inequality in society. Stigma and discrimination are in part 
the result of drug control policies. According to the United Nations Office on Drugs 
and Crime (UNODC),22 ‘while drug addiction, organised crime and terrorism 
undermine a host of human rights, responses to these problems can only be effective 
where they respect and restore the rights of those who are most vulnerable’.
There are no systematic reviews of the implementation of the rights of people with 
drug problems or those affected by drugs that are outlined in the international human 
rights documents, including the EU Charter on Fundamental Rights. CSF members 
were able to list several examples, identified in at least one or a few EU Member 
States, that suggest the need to strengthen human rights mechanisms and their 
implementation:
• discrimination against drug users by medical personnel, and 
non-evidence-based criteria that exclude drug users from some kinds of 
healthcare;23
• defunding of low threshold services once international donors cease 
operating in a country;24 harm reduction services remain geographically 
inaccessible in some parts of EU Member States in community settings25 and 
is generally not available in prison settings in most EU Member States26 
despite the evidence base;
• poor economic and social protection for people dependent on drugs following 
rehabilitation, and counterproductive measures such as the imposition of 
accumulated fines for drug use that undermine the ability of individuals to 
support themselves;27
•
• poor access to healthcare and drug demand reduction for communities who 
are badly affected by drugs and face serious discrimination in society, such 
22 Drug control, crime prevention and criminal justice: A Human Rights perspective. Note by UNODC 
Executive Director to the Commission on Narcotic Drugs & the Commission on Crime Prevention and 
Criminal Justice. E/CN.7/2010/CRP.6–E/CN.15/2010/CRP.1. 3 March 2010.
23 For example, see Reimer, J, Schulte, B et al. Guidelines for the Treatment of Hepatitis C Virus 
Infection in Injection Drug Users: Status Quo in the European Union Countries. Clinical Infectious  
Diseases. 2005:40 (Suppl 5) S373-8. .
24 For example, see Romania case study in ITPC & ICASO. Global Fund Country Coordinating 
Mechanisms: A Prescription for Change in a Time of Promise … and Peril. March 2012 (in print).
25 For example, in the 2011 Annual report the EMCDDA indicates that several Central and Eastern 
European states and Sweden report no access to clean needles in some parts of the countries. .
26 For example, see Report from the Commission to the European Parliament and the Council on the  
implementation of the Council Recommendation of 18 June 2003 on the prevention and reduction of  
health-related harm associated with drug dependence. Brussels, 18.4.2007 COM(2007) 199 final, 
which says: ‘harm reduction interventions in prisons within the European Union are still not in 
accordance with the principle of equivalence adopted by UN General Assembly, UNAIDS/ WHO and 
UNODC, which calls for equivalence between health services and care (including harm reduction) 
inside prison and those available to society outside prison. Therefore, it is important for the countries to 
adapt prison-based harm reduction activities to meet the needs of drug users and staff in prisons and 
improve access to services.’
27 I Can Live Coalition. Letter No 2007-045 to Ministry of Justice, Law and Enforcement Committee of 
the Parliament of the Republic of Lithuania & Lithuanian Chamber of Private Enforcement Agents 
Regarding Legal Regulation of Enforcement Process (in Lithuanian). 05 October 2007. 
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as street-based sex workers throughout Europe28 and Roma in Central and 
Eastern European states;29
•
• a lack of intensive support services for children and adolescents who have 
parents with a drug problem and who are at risk of developing drug and other 
problems of their own.30
Implementation
 The Member States should establish mechanisms to protect the rights of people 
affected by drugs, including but not limited to the revision of legislation on 
ensuring universal primary care for all, and raising awareness in settings where 
people affected by drugs face discrimination.
 Resources should be allocated to incorporating such measures into drug action 
plans.
 Civil society, including people affected by drugs and human rights groups, should 
be involved in identifying and prioritising mechanisms for rights protection.
 The Commission should support the Member States and civil society with respect 
to the exchange of good practice and the collection of evidence in the field.  
11. The human rights of people affected by drugs in the Member States should 
be monitored systematically and regularly, and should inform changes in drug 
policy and practices.
Rationale: There is a need for systematic monitoring of the human rights of people 
affected by drugs. Based on the explicit assessment of the rights most affected, 
monitoring and evaluation could include focusing on: the rights of people who are 
affected by drugs to have the highest attainable standard of physical and mental 
health; the rights of the child to protection; the right to justice and legal support as 
well as the rights to education and to fair and just working conditions; the right to 
social security and social assistance; the right to a fair trial and standards of due 
process; the right to avoid torture, cruel, inhumane or degrading treatment, 
punishment or arbitrary detention; the right to non-discrimination; as well as cultural 
or indigenous rights. Civil society has vast experience in monitoring fundamental 
rights in other fields and in the field of drug policy in other regions.
Implementation
 The Member States should integrate mechanisms and indicators for fundamental 
rights  monitoring  in  the  EU  and  national  drug  strategies,  including  their 
evaluation.
 The European Commission should support the Member States by recommending 
mechanisms  and  indicators  and  assessing  progress  in  the  integration  of 
fundamental rights monitoring mechanisms in national legislation, as well as by 
providing support for independent fundamental rights initiatives led by civil society 
and researchers.
 Civil  society  groups  should  be  involved  in  defining  mechanisms  and  unified 
indicators,  as  well  as  evaluating  human rights  mechanisms with  independent 
data.
28 Mellor, R and Lovell, A (2011). Health Promotion International. The lived experience of UK street-
based sex workers and the health consequences: an exploratory study. Accessed at: 
http://heapro.oxfordjournals.org/content/early/2011/07/03/heapro.dar040.abstract .
29 For example, see European Roma Rights Centre. Ambulance not on the way. The disgrace of 
healthcare for Roma in Europe, September 2006.
30 Pagano et al (2007). Impact of parental history of substance use disorders on the clinical course of 
anxiety disorders. Substance Abuse Treatment, Prevention, and Policy 2007, 2:13 .
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 The European Commission should conduct a human rights assessment of drug 
policies at EU level consult the Member States, the European Parliament, civil 
society  and  other  stakeholders  to  determine  specific  measures  aimed  at 
improving fundamental rights in the drugs field.
Children and Young People
12. Special attention should be given to the design, implementation and 
evaluation of services and policies benefiting children and young people.
Rationale: All EU Member States have ratified the UN Convention on the Rights of 
the Child, which in Article 33 requires ‘all appropriate measures, including legislative, 
administrative, social and educational measures, to protect children from the illicit 
use of narcotic drugs and psychotropic substances as defined in the relevant 
international treaties, and to prevent the use of children in the illicit production and 
trafficking of such substances’.
Children’s services across the EU should ensure children’s right to harmonious 
development (including support for learning, housing, family problems) and address 
the root causes of drug problems related to poverty and social exclusion.31 The 
current level of services for children and young people affected by drugs remains 
inadequate — available services do not always seek to respond to the specific needs 
of children and young people, while children and young people face barriers to 
accessing these services.
Implementation
 The European Commission should support the exchange of good practice and 
efforts to monitor the quality of services, as well as advocacy for sustained 
funding for evidence-based prevention and other drug demand reduction 
measures for children and young people, particularly those in vulnerable 
situations.
 The Member States should integrate mechanisms and indicators for Article 33 of 
the UN Convention on the Rights of the Child in their drug strategies, including 
evaluation.
 The Member States should identify synergies between drug and youth policies at 
national and EU levels, encouraging the direct involvement of children and young 
people in drug policies and in service design and evaluation.  
 The Member States should introduce drug legislation that treats children and 
young people as ‘at risk’ and in need of support and care rather than as criminals. 
The European Commission should help to identify such legislation and good 
practice mechanisms to implement it, as well as to support efforts to share 
lessons learnt among Member States.32
Services
13. EU minimum quality standards for drug demand reduction need to be 
adopted and effectively implemented.
31 EMCDDA (2011). Children’s Voices. Experiences and perceptions of European children on drug 
and alcohol issues. Luxembourg: The Publications Office of the European Union, 2010.
32 EMCDDA (2008). Drugs and vulnerable groups of young people. Selected Issue. Luxembourg: 
Office for Official Publications of the European Communities, 2008.
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Rationale: While there is a wide range of high-quality good practice across Europe, 
there continues to be practice which falls short of what could be described as a 
minimum standard, resulting in less than optimum outcomes.
The European Action Plan on Drugs 2009-2012 agreed by the EU Member States 
asked the European Commission to develop an EU consensus on minimum quality 
standards in the field of drug demand reduction. A set of recommendations was 
developed within the project called ‘Study on the development of an EU framework 
for minimum quality standards and benchmarks in drug demand reduction’ (EQUS). 
Implementation
 The European Commission should facilitate the adoption of EU minimum quality 
standards for drug demand reduction.
 The Member States should take steps to implement those standards at national 
level and fund mechanisms to ensure high quality drug demand reduction 
programmes.
 The European Commission should support and monitor the implementation of 
those standards. This should include funding for relevant cross-country capacity 
strengthening and support initiatives, particularly those taken by civil society.
14. Swift and easy access to a range of evidence-based services for people 
with drug problems aimed at reducing health-related harms (HIV, hepatitis and 
overdose) should be guaranteed across Europe. These services should include 
residential and community rehabilitation, social reintegration, housing support, 
substitute medication treatment and needle exchange, along with connections 
to a range of other services.  
Rationale: There is strong evidence in support of investment in services for problem 
drug users. The National Treatment Outcome Research project in the UK found that 
for each euro spent on services there were savings of ten euros on other costs to 
society. There is evidence that the economic recession is having an adverse impact 
on Europe’s drug problem; this impact might deepen as the socio-economic situation 
worsens. It is therefore vital that funding for drug-related services continue: if 
services are reduced, short-term savings achieved by cutting drug demand reduction 
are outweighed by long-term costs to society, including major health and social 
harms such as hepatitis C, HIV and overdose, drug-related crime, or loss of housing. 
While institution-based and medical services form an important part of drug services, 
other types of service delivery, such as informal, peer-to-peer or community services 
are just as important in reducing drug demand. A large share of low-threshold drug 
services are run by non-governmental organisations, which often depend on national 
and local funding. Some CSF members have already reported reduced availability of 
drug-related services in their countries. Moreover, in countries where until recently 
international funding was made available to support the expansion of cost-effective, 
evidence-based services, replacement national funding has not been forthcoming.
Implementation
 The Member States should ensure sustainable and adequate funding to support 
swift access to a range of high-quality services to people with drug problems. 
Funding from European structural funds could be used if needed and appropriate. 
Funding for drug demand reduction should not be reduced amid budget cuts 
caused by current economic difficulties.
 The Member States should support mechanisms used in contracting drug 
demand reduction services from civil society organisations.
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 The European Commission should promote scientific evidence for drug demand 
reduction services across Europe.  
 The European Commission should fund European networks for exchange and 
knowledge transfer.
Monitoring and Evaluation
15. The European Union should promote the evaluation of progress and impact 
as an integral element of drug policy at national, EU and international levels.
Rationale: While evaluation is now better integrated into drug policy documents, not 
all Member States conduct independent evaluations of the implementation of national 
strategies and even fewer have evaluated their impact. Given the complexity of drugs 
issues and their correlation with social and other problems, evaluation should 
address a range of aspects including: law enforcement, human and children’s rights, 
ethics, legislation and rule of law, health, social inequalities, economics, cultural and 
social aspects, education, international relations and others. Evaluation is beneficial 
not only at policy level but also at programme and service level, as it helps to 
establish clear criteria for results and fosters transparency and accountability. 
Projects that achieve measurable results in line with the objectives of EU and 
national drug strategies should be encouraged and expanded.
Implementation
 The Member States should commission independent and external evaluations of 
national drug policies (including impact evaluations) and conduct multi-
stakeholder consultations to determine specific steps towards more effective and 
evidence-based policies.
 The European Commission should support the evaluation of national drug policy 
progress and impact. It should also commission an evaluation of the impact of EU 
drugs policy. The European Commission should use the evaluation data to 
facilitate an open and objective debate on the direction of drug policy, including 
alternatives to current approaches.
 The Member States and the European Commission should support the 
evaluation of programmes within their funding schemes and envisage 
mechanisms to utilise the evaluation results to develop further drug demand 
reduction.
 The European Commission should support the Member States and cross-country 
initiatives that promote effectiveness and cost-effectiveness evaluation of 
interventions, where data are still limited, and promote the results as a means of 
strengthening policies and programmes.
 The EU Civil Society Forum on drugs as well as national civil society groups 
should be meaningfully engaged in evaluation initiatives and debates on the 
future of drug policy.
International Cooperation
16. The European Union should actively promote its drug policy principles and 
approaches at international level.
Rationale: There is also a great wealth of experience and expertise within the EU on 
the development of drug strategies and the implementation of evidence-based 
programmes.
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The EU drug strategy contains a number of broad principles that set a good example 
for any national or international policies: coordinated and integrated programmes; 
investment in developing evidence and research; and a balance of activities between 
supply reduction, demand reduction and harm reduction, including the constant 
assessment and review of results and effectiveness.
Implementation:
 The European Union, particularly the European External Action Service (EEAS), 
should play a greater role in promoting the ‘balanced approach’ of the agreed EU 
drug policy in other countries, regional organisations, such as the Organisation of 
American States and the African Union, and in United Nations discussions.
 The Member States and the EU institutions should make greater efforts to identify 
the best elements of EU policies and programmes and share these experiences 
with policy makers and professionals in other countries around the world.
 In particular, the creation of the EEAS provides an opportunity to take this aspect 
of the strategy forward, through its own delegations, but also through the careful 
planning of development aid programmes.
Signatories (in alphabetic order):
Anke van Dam AIDS Foundation East-West
Carmen Martínez Perza Andalusian Federation ENLACE
José Queiroz APDES
Thierry Charlois Association Française de Réduction des risques (AFR)
Frans Koopmans De Hoop Foundation
Andrei Nevskii Drug Abuse Prevention Centre
Deniz Uyanik EATG
Jorgen Svidén ECAD
Simona Merkinaite EHRN 
Frederik Polak ENCOD
thomas Legl euro -tc
Fay Watson Europe Against Drugs
Raminta Stuikyte European AIDS Treatment Group (EATG)
Mark BURTON-PAGE European Forum for Urban Security
Monica Luppi Fondazione San Patrignano 
Eberhard Schatz Foundation de Regenboog Groep
Maria Phelan Harm Reduction International
Vlatko Dekov HOPS
Peter Sarosi Hungarian Civil Liberties Union
Jane Francis ICOS
Marie Nougier International Drug Policy Consortium
eliot albers International Network of People who Use Drugs
Amador Calafat Irefrea
Maurizio Coletti Itaca
Edoardo Polidori Itaca Italia
Jeff Lee Mentor Foundation
Ingo Stockel PARSEC Consortium
Alexandra Roubalova Prev-Centrum, NGO
Valentin Simionov Romanian Harm Reduciton Network
David Liddell SDF
Raquel Munto Socidrogalcohol
Arian Boci STOP AIDS NGO in Albania
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Pedro Quesada UNAD - Spain
Matej Košir UTRIP
Leena Haraké WOCAD
Annexes and comments to the text by Civil Society Forum Members (in alphabetic 
order):
AFR and [xx]other organisations  provided a statement regarding prevention and harm 
reduction in recreational settings. See annex I
EATG expressed support to the Statement of the EU HIV/AIDS Civil Society Forum 
statement on the future drug policies in the EU and beyond: “Putting health and human rights 
first', also addressing the meaningful involvement of people who use drugs.
ENCOD didn't sign the document, because in ENCOD's view the recommendations are 
incomplete because they avoid the central and crucial issue in international drug policy, 
namely the question which regulatory system is best capable of diminishing health risks and 
social problems connected with drug use. ENCOD's position is explained in annex II
EURAD: Page 7: Point 6: Diversion from prosecution should be provided for possession of 
small amounts of drugs for personal use Comment “Europe Against Drugs believes that 
people who use drugs should be offered an effective route to treatment and recovery at every 
stage of their contact with the criminal justice system”  Page 8: "Based on such consultation, 
action should be taken to change legislation and other policy where needed, and to ensure that 
new policy is supported within the national drug policy framework" Comment: "Europe 
Against Drugs supports the piloting and roll out of effective court supervised diversion 
programmes as well as access to treatment and recovery services"  Page 13: Point 14: Swift 
and easy access to a range of evidence-based services for people with drug problems and for 
reducing health-related harms (HIV, hepatitis and overdose) should be guaranteed across 
Europe. These services should etc.. Comment: "Europe Against Drugs supports the use of 
harm reduction interventions when they are evidence based and when they are placed within a 
framework of wider health and social support which aim to help people achieve full recovery" 
Page 9: It is therefore necessary to provide drug demand reduction services for problem drug 
users in prison Comment: "Europe Against Drugs urges governments to ensure the provision 
of drug free prisons"
The position of EURAD and 7 other organisations regarding an integrated approach to EU 
drug policy is explained in annex III.
IDPC:
16 members of the CSF (Civil Society Forum on Drugs) recommend that the 
decriminalisation of possession of small amounts should be considered. Their position is 
explained in annex IV.
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